COVID-19: CARE Consortium
Boehringer Ingelheim is a member of the CARE (Corona Accelerated R&D in Europe) consortium and is leading the work stream of the consortium focusing on the development of virus neutralizing antibodies. Furthermore, the company provided antiviral molecules from its legacy HIV and HCV portfolio and small molecule candidates from a complete screen of its molecule library.
Clive R. Wood, Ph.D., Corporate Senior Vice President and Global Head of Discovery Research at Boehringer Ingelheim said,
“The CARE consortium aims to unleash the power of open science and collaboration in the service of society. We will work quickly and decisively in an unprecedented spirit of co-operation with our partners in academia and industry to defeat the unprecedented menace of COVID-19 and other serious coronavirus diseases.”
The Innovative Medicines Initiative (IMI) initiated a fast-track call for proposals on the development of therapeutics and diagnostics to tackle current and future coronavirus outbreaks. In response to the fast-track call, the CARE consortium supported by the IMI public-private partnership has been formed. With a grant totaling € 75.8 million, CARE is funded by cash contributions from the European Union (EU) and cash and in-kind contributions from eleven European Federation of Pharmaceutical Industries and Associations (EFPIA) companies and three IMI-Associated Partners. CARE launched to accelerate therapy development against COVID-19 and future coronavirus threats. It is a five-year project bringing together 37 partners from academia and industry and integrates the partner’s COVID-19 projects ongoing since February 2020.
Acknowledgement
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 101005077. The JU receives support from the European Union’s Horizon 2020 research and innovation programme, EFPIA, BILL & MELINDA GATES FOUNDATION, GLOBAL HEALTH DRUG DISCOVERY INSTITUTE, UNIVERSITY OF DUNDEE.